Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet
2
조회
0
다운로드
11
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES: Obesity-associated insulin resistance is a strong risk factor for type 2 diabetes mellitus. The aimof this study was to investigate the effect of myricetin on adiposity, insulin resistance, and inflammatory markers in micewith diet-induced insulin resistance. MATERIALS/METHODS: Five-week-old male C57BL/6J mice were fed a basal diet, a high-fat, high-sucrose (HFHS) diet, or theHFHS diet containing 0.06% myricetin or 0.12% myricetin for 12 weeks after a 1-week adaptation, and body weight and foodintake were monitored. After sacrifice, serum lipid profiles, glucose, insulin, adipocyte-derived hormones, and proinflammatorycytokines were measured. The homeostasis model assessment for insulin resistance (HOMA-IR) was determined. RESULTS: Myricetin given at 0.12% of the total diet significantly reduced body weight, weight gain, and epidydimal whiteadipose tissue weight, and improved hypertriglyceridemia and hypercholesterolemia without a significant influence on foodintake in mice fed the HFHS diet. Serum glucose and insulin levels, as well as HOMA-IR values, decreased significantly by0.12% myricetin supplementation in mice fed the HFHS diet. Myricetin given at 0.12% of the total diet significantly reducedserum levels of leptin, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in mice fed the HFHS diet. CONCLUSIONS: These findings suggest that myricetin may have a protective effect against diet-induced obesity and insulinresistance in mice fed HFHS diet, and that alleviation of insulin resistance could partly occur by improving obesity and reducingserum proinflammatory cytokine levels.
Abstract
BACKGROUND/OBJECTIVES: Obesity-associated insulin resistance is a strong risk factor for type 2 diabetes mellitus. The aimof this study was to investigate the effect of myricetin on adiposity, insulin resistance, and inflammatory markers in micewith diet-induced insulin resistance. MATERIALS/METHODS: Five-week-old male C57BL/6J mice were fed a basal diet, a high-fat, high-sucrose (HFHS) diet, or theHFHS diet containing 0.06% myricetin or 0.12% myricetin for 12 weeks after a 1-week adaptation, and body weight and foodintake were monitored. After sacrifice, serum lipid profiles, glucose, insulin, adipocyte-derived hormones, and proinflammatorycytokines were measured. The homeostasis model assessment for insulin resistance (HOMA-IR) was determined. RESULTS: Myricetin given at 0.12% of the total diet significantly reduced body weight, weight gain, and epidydimal whiteadipose tissue weight, and improved hypertriglyceridemia and hypercholesterolemia without a significant influence on foodintake in mice fed the HFHS diet. Serum glucose and insulin levels, as well as HOMA-IR values, decreased significantly by0.12% myricetin supplementation in mice fed the HFHS diet. Myricetin given at 0.12% of the total diet significantly reducedserum levels of leptin, tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in mice fed the HFHS diet. CONCLUSIONS: These findings suggest that myricetin may have a protective effect against diet-induced obesity and insulinresistance in mice fed HFHS diet, and that alleviation of insulin resistance could partly occur by improving obesity and reducingserum proinflammatory cytokine levels.
참고문헌 (35)
- Danaei G, "National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants", Lancet, 378, pp.31~40 (2011)
- Weyer C, "The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus", J Clin Invest, 104, pp.787~794 (1999)
- Lebovitz HE, "Insulin resistance: definition and consequences", Exp Clin Endocrinol Diabetes, 109(Suppl 2), pp.S135~S148 (2001)
- Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome", Diabetes Care, 24, pp.683~689 (2001)
- Garg A, "Management of dyslipidemia in NIDDM", Diabetes Care, 13, pp.153~169 (1990)
- Lebovitz HE, "Treating hyperglycemia in type 2 diabetes: new goals and strategies", Cleve Clin J Med, 69, pp.809~820 (2002)
- Qatanani M, "Mechanisms of obesity-associated insulin resistance: many choices on the menu", Genes Dev, 21, pp.1443~1455 (2007)
- Goossens GH, "The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance", Physiol Behav, 94, pp.206~218 (2008)
- Ostlund RE Jr, "Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates", J Clin Endocrinol Metab, 81, pp.3909~3913 (1996)
- Hotamisligil GS, "Tumor necrosis factor alpha: a key component of the obesity-diabetes link", Diabetes, 43, pp.1271~1278 (1994)
- Kern PA, "Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance", Am J Physiol Endocrinol Metab, 280, pp.E745~E751 (2001)
- Weyer C, "Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia", J Clin Endocrinol Metab, 86, pp.1930~1935 (2001)
- Sheng T, "Adiponectin and its association with insulin resistance and type 2 diabetes", J Genet Genomics, 35, pp.321~326 (2008)
- Tilg H, "Insulin resistance, inflammation, and nonalcoholic fatty liver disease", Trends Endocrinol Metab, 19, pp.371~379 (2008)
- Xu H, "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance", J Clin Invest, 112, pp.1821~1830 (2003)
- Kanda H, "MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity", J Clin Invest, 116, pp.1494~1505 (2006)
- Harnly JM, "Flavonoid content of U.S. fruits, vegetables, and nuts", J Agric Food Chem, 54, pp.9966~9977 (2006)
- Lin J, "Flavonoid intake and colorectal cancer risk in men and women", Am J Epidemiol, 164, pp.644~651 (2006)
- Ko SY, "Myricetin suppresses LPS-induced MMP expression in human gingival fibroblasts and inhibits osteoclastogenesis by downregulating NFATc1 in RANKL-induced RAW 264.7 cells", Arch Oral Biol, 57, pp.1623~1632 (2012)
- Bok Yun Kang, "Inhibition of Interleukin-12 Production in Mouse Macrophages via Decreased Nuclear Factor-κB DNA Binding Activity by Myricetin, a Naturally Occurring Flavonoid", Archives of Pharmacal Research, 28(3), pp.274~279 (2005), 대한약학회
- Lee YS, "Myricetin inhibits IL-1beta-induced inflammatory mediators in SW982 human synovial sarcoma cells", Int Immunopharmacol, 10, pp.812~814 (2010)
- Liu IM, "Myricetin, a naturally occurring flavonol, ameliorates insulin resistance induced by a high-fructose diet in rats", Life Sci, 81, pp.1479~1488 (2007)
- Chang CJ, "Myricetin increases hepatic peroxisome proliferator-activated receptor α protein expression and decreases plasma lipids and adiposity in rats", Evid Based Complement Alternat Med, 2012, pp.787152~ (2012)
- Surwit RS, "Diet-induced type II diabetes in C57BL", 6J mice, 1988, pp.37, 1163~1167
- Surwit RS, "Control of expression of insulin resistance and hyperglycemia by different genetic factors in diabetic C57BL", 6J mice, 1991, pp.40, 82~87
- Schreyer SA, "LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice", Am J Physiol Endocrinol Metab, 282, pp.E207~E214 (2002)
- Haffner SM, "The homeostasis model in the San Antonio Heart Study", Diabetes Care, 20, pp.1087~1092 (1997)
- Yang ZH, "Diet high in fat and sucrose induces rapid onset of obesity-related metabolic syndrome partly through rapid response of genes involved in lipogenesis, insulin signalling and inflammation in mice", Diabetol Metab Syndr, 4, pp.32~ (2012)
- Anderson JW, "Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies", J Am Coll Nutr, 22, pp.331~339 (2003)
- Sato A, "Antiobesity effect of eicosapentaenoic acid in high-fat", high-sucrose diet-induced obesity: importance of hepatic lipogenesis, 2010, pp.59, 2495~2504
- Pelleymounter MA, "Effects of the obese gene product on body weight regulation in ob", ob mice, 1995, pp.269, 540~543
- Myers MG Jr, "Obesity and leptin resistance: distinguishing cause from effect", Trends Endocrinol Metab, 21, pp.643~651 (2010)
- Unger RH, "Lipotoxic diseases", Annu Rev Med, 53, pp.319~336 (2002)
- Senn JJ, "Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes", J Biol Chem, 278, pp.13740~13746 (2003)
- Hajer GR, "Adipose tissue dysfunction in obesity, diabetes, and vascular diseases", Eur Heart J, 29, pp.2959~2971 (2008)